BioXcel Therapeutics Inc. (BTAI) 近日宣布,美国食品药品监督管理局(FDA)已正式受理其旗下药物Igalmi®用于居家环境的补充新药申请(sNDA)。这一进展标志着该药物在拓展临床应用场景方面迈出重要一步。
BioXcel Therapeutics Inc. (BTAI) 近日宣布,美国食品药品监督管理局(FDA)已正式受理其旗下药物Igalmi®用于居家环境的补充新药申请(sNDA)。这一进展标志着该药物在拓展临床应用场景方面迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.